Sagimet Biosciences Inc.
SGMT
$2.21
$0.199.41%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -100.00% | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -100.00% | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -100.00% | -- | -- | -- |
| SG&A Expenses | 23.51% | 48.13% | 128.23% | 156.43% | 111.26% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 66.32% | 49.13% | 32.46% | 19.49% | 5.43% |
| Operating Income | -77.14% | -59.53% | -25.54% | -12.61% | 1.01% |
| Income Before Tax | -63.46% | -39.36% | -4.34% | 1.53% | 8.60% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -63.46% | -39.36% | -4.34% | 1.53% | 8.60% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -63.46% | -39.36% | -4.34% | 1.53% | 8.60% |
| EBIT | -77.14% | -59.53% | -25.54% | -12.61% | 1.01% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 98.00% | 98.84% | 99.22% | 76.05% | 56.37% |
| Normalized Basic EPS | 98.00% | 98.84% | 99.22% | 76.05% | 56.37% |
| EPS Diluted | 98.00% | 98.84% | 99.22% | 76.05% | 56.37% |
| Normalized Diluted EPS | 98.00% | 98.84% | 99.22% | 76.05% | 56.37% |
| Average Basic Shares Outstanding | 198.20% | 521.45% | 13,691.46% | 9,483.54% | 5,589.37% |
| Average Diluted Shares Outstanding | 198.20% | 521.45% | 13,691.46% | 9,483.54% | 5,589.37% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |